JAK/TYK2

Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…

Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as…

Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) presented on the first day of…

Translating targeted therapy from bench to bedside has been more problematic in systemic lupus erythematosus (SLE) than other autoimmune diseases, with many theoretically well-founded agents…

Are Tyk2 inhibitors JAK inhibitors? Yes, no, maybe Answer Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family. These molecules regulate signal transduction downstream of receptors for…

One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial…

At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). I will be sharing the details of these studies once they are presented. There are new therapies that…